Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Oscar Fernandez, Thomas Berger, Hans-Peter Hartung & Norman Putzki. (2012) Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology 5:6, pages 649-665.
Read now
Read now
Keith C Hayes. (2011) Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7, pages 229-239.
Read now
Read now
Nancy L Kuntz, Dorothee Chabas, Bianca Weinstock-Guttman, Tanuja Chitnis, E Ann Yeh, Lauren Krupp, Jayne Ness, Moses Rodriguez & Emmanuelle Waubant. (2010) Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy 11:4, pages 505-520.
Read now
Read now
Articles from other publishers (27)
Junfei Li, Yajie Xie, Xiaoran Zou, Zhengze Li, Wenbo Liu, Guodong Liu, Mengjiao Ma & Yudong Zheng. (2023) Ultrasonic/electrical dual stimulation response nanocomposite bioelectret for controlled precision drug release. Materials Today Bio 20, pages 100665.
Crossref
Crossref
Mashanipalya G. Jagadeeshaprasad, Prem Kumar Govindappa, Amanda M. Nelson, Mark D. Noble & John C. Elfar. (2022) 4-Aminopyridine Induces Nerve Growth Factor to Improve Skin Wound Healing and Tissue Regeneration. Biomedicines 10:7, pages 1649.
Crossref
Crossref
Yulun Huang, Lin Qi, Mari Kogiso, Yuchen Du, Frank K. Braun, Huiyuan Zhang, L. Frank Huang, Sophie Xiao, Wan‐Yee Teo, Holly Lindsay, Sibo Zhao, Patricia Baxter, Jack M. F. Su, Adekunle Adesina, Jianhua Yang, Sebastian Brabetz, Marcel Kool, Stefan M. Pfister, Murali Chintagumpala, Laszlo Perlaky, Zhong Wang, Youxin Zhou, Tsz‐Kwong Man & Xiao‐Nan Li. (2021) Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. Advanced Science 8:23, pages 2101923.
Crossref
Crossref
Tor-Arne Hegvik, Kai Waløen, Sunil K. Pandey, Stephen V. Faraone, Jan Haavik & Tetyana Zayats. (2019) Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Molecular Psychiatry 26:8, pages 4004-4015.
Crossref
Crossref
Victor W. Mark. (2021) Retention of Physical Gains in the Community Following Physical Training for Multiple Sclerosis: A Systematic Review and Implications. Seminars in Neurology 41:02, pages 177-188.
Crossref
Crossref
Ivanka Kostadinova & Nikolai Danchev. (2019) 4-aminopyridine – the new old drug for the treatment of neurodegenerative diseases. Pharmacia 66:2, pages 67-74.
Crossref
Crossref
Hajar G. Ghalehshahi, Saeed Balalaie, Hamid R. Sohbati, Homa Azizian & Mohammad S. Alavijeh. (2019) Synthesis, CYP 450 evaluation, and docking simulation of novel 4-aminopyridine and coumarin derivatives. Archiv der Pharmazie 352:3, pages 1800247.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
643
766
.
Victor W. Mark, Edward Taub, Gitendra Uswatte, David M. Morris, Gary R. Cutter, Terrie L. Adams, Mary H. Bowman & Staci McKay. (2018) Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function. Neurorehabilitation and Neural Repair 32:3, pages 223-232.
Crossref
Crossref
Manav Malhotra, Pankaj Ghai, Balasubramanian Narasimhan & Aakash Deep. (2016) Dalfampridine: Review on its recent development for symptomatic improvement in patients with multiple sclerosis. Arabian Journal of Chemistry 9, pages S1443-S1449.
Crossref
Crossref
Björn Zörner, Linard Filli, Katja Reuter, Sandra Kapitza, Lilla Lörincz, Tabea Sutter, David Weller, Melinda Farkas, Christopher S Easthope, Adam Czaplinski, Michael Weller & Michael Linnebank. (2016) Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Multiple Sclerosis Journal 22:11, pages 1463-1475.
Crossref
Crossref
Jessie M. Huisinga, Rebecca J. St George, Rebecca Spain, Shannon Overs & Fay B. Horak. (2014) Postural Response Latencies Are Related to Balance Control During Standing and Walking in Patients With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation 95:7, pages 1390-1397.
Crossref
Crossref
Henrik Boye Jensen, Mads Ravnborg, Ulrik Dalgas & Egon Stenager. (2013) 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Therapeutic Advances in Neurological Disorders 7:2, pages 97-113.
Crossref
Crossref
María Teresa Frejo, Javier del Pino, Margarita Lobo, Jimena García, Miguel Andrés Capo & María Jesús Díaz. (2014) Liver and kidney damage induced by 4-aminopyridine in a repeated dose (28 days) oral toxicity study in rats: Gene expression profile of hybrid cell death. Toxicology Letters 225:2, pages 252-263.
Crossref
Crossref
Alexander Velumian & Marina Samoilova. 2014. White Matter Injury in Stroke and CNS Disease. White Matter Injury in Stroke and CNS Disease
3
38
.
Amanda Farag & Allison Averill. (2013) Dalfampridine. American Journal of Physical Medicine & Rehabilitation 92:7, pages 635-636.
Crossref
Crossref
Valentina Tomassini, Paul M. Matthews, Alan J. Thompson, Daniel Fuglø, Jeroen J. Geurts, Heidi Johansen-Berg, Derek K. Jones, Maria A. Rocca, Richard G. Wise, Frederik Barkhof & Jacqueline Palace. (2012) Neuroplasticity and functional recovery in multiple sclerosis. Nature Reviews Neurology 8:11, pages 635-646.
Crossref
Crossref
Carrie Hersh & Alex Rae-Grant. (2012) Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5:4, pages 199-204.
Crossref
Crossref
Alexander G. Rabchevsky, Samir P. Patel & Joe E. Springer. (2011) Pharmacological interventions for spinal cord injury: Where do we stand? How might we step forward?. Pharmacology & Therapeutics 132:1, pages 15-29.
Crossref
Crossref
Cosmin A. Tegla, Cornelia Cudrici, Monika Rozycka, Katerina Soloviova, Takahiro Ito, Anil K. Singh, Aamer Khan, Philippe Azimzadeh, Maria Andrian-Albescu, Anver Khan, Florin Niculescu, Violeta Rus, Susan I.V. Judge & Horea Rus. (2011) C5b-9-activated, Kv1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation. Experimental and Molecular Pathology 91:1, pages 335-345.
Crossref
Crossref
Tanuja Chitnis, Lauren Krupp, Ann Yeh, Jennifer Rubin, Nancy Kuntz, Jonathan B. Strober, Dorothee Chabas, Bianca Weinstock-Guttmann, Jayne Ness, Moses Rodriguez & Emmanuelle Waubant. (2011) Pediatric Multiple Sclerosis. Neurologic Clinics 29:2, pages 481-505.
Crossref
Crossref
Andrew R. Blight. (2011) Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic Advances in Neurological Disorders 4:2, pages 99-109.
Crossref
Crossref
M.A. Sahraian, A.H. Maghzi, M. Etemadifar & A. Minagar. (2011) Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis. Journal of Central Nervous System Disease 3, pages JCNSD.S4868.
Crossref
Crossref
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka & Jörg Kraus. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discovery Today 16:1-2, pages 8-21.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2011. The Handbook of Neuroprotection. The Handbook of Neuroprotection
409
483
.
Gabrièle Piaton, Robert M. Gould & Catherine Lubetzki. (2010) Axon‐oligodendrocyte interactions during developmental myelination, demyelination and repair. Journal of Neurochemistry 114:5, pages 1243-1260.
Crossref
Crossref
L. Husseini, V.I. Leussink, B.C. Kieseier & H.-P. Hartung. (2010) 4-Aminopyridin (Fampridin)4-Aminopyridine (Fampridine). Der Nervenarzt 81:2, pages 203-211.
Crossref
Crossref